Damora Therapeutics (DMRA) Cash from Operations (2019 - 2026)
Damora Therapeutics posted quarterly Cash from Operations of 20600000.0 for Q1 2026, down 758.33% year-on-year from 3129113.92 in Q1 2025, and down 3688.85% on a QoQ basis from 574000.0 in Q4 2025.
Damora Therapeutics (DMRA) has 8 years of Cash from Operations data on file, last reported at 20600000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations fell 758.33% year-over-year to 20600000.0; the trailing twelve-month figure through Mar 2026 stood at 24926000.0 (down 65.07% YoY), and the FY2025 full-year result was 6726000.0, up 63.84% from the prior year.
- Cash from Operations for Q1 2026 stood at 20600000.0, down from 574000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 574000.0 in Q4 2025 and bottomed at 20600000.0 in Q1 2026.
- The 5-year median for Cash from Operations is 6797000.0 (2022), against an average of 7397529.41.
- The widest annual swing landed in 2025, when Cash from Operations surged 111.68%; it then sank 758.33% in 2026.
- A 5-year view of Cash from Operations shows it stood at 11448000.0 in 2022, then declined by 0.13% to 11463000.0 in 2023, then surged by 57.14% to 4913000.0 in 2024, then soared by 111.68% to 574000.0 in 2025, then sank by 3688.85% to 20600000.0 in 2026.
- The last three Cash from Operations figures came in at 20600000.0 (Q1 2026), 574000.0 (Q4 2025), and 2600000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Damora Therapeutics | 853.36 Mn | 650.97 Mn | - | -20.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.60 Mn |
| Mar 31, 2026 | -20.60 Mn |
| Dec 31, 2025 | 574,000.00 |
| Dec 31, 2025 | 574,000.00 |
| Sep 30, 2025 | -2.60 Mn |
| Sep 30, 2025 | -2.60 Mn |
| Jun 30, 2025 | -2.30 Mn |
| Jun 30, 2025 | -2.30 Mn |
| Mar 31, 2025 | -2.40 Mn |
| Mar 31, 2025 | -2.40 Mn |
| Dec 31, 2024 | -4.91 Mn |
| Dec 31, 2024 | -4.91 Mn |
| Sep 30, 2024 | -3.69 Mn |
| Sep 30, 2024 | -3.69 Mn |
| Jun 30, 2024 | -4.10 Mn |
| Jun 30, 2024 | -4.10 Mn |
| Mar 31, 2024 | -5.90 Mn |
| Mar 31, 2024 | -5.90 Mn |
| Dec 31, 2023 | -11.46 Mn |
| Dec 31, 2023 | -11.46 Mn |
| Sep 30, 2023 | -8.45 Mn |
| Sep 30, 2023 | -8.45 Mn |
| Jun 30, 2023 | -7.88 Mn |
| Jun 30, 2023 | -7.88 Mn |
| Mar 31, 2023 | -9.10 Mn |
| Mar 31, 2023 | -9.10 Mn |
| Dec 31, 2022 | -11.45 Mn |
| Dec 31, 2022 | -11.45 Mn |
| Sep 30, 2022 | -9.85 Mn |
| Sep 30, 2022 | -9.85 Mn |
| Jun 30, 2022 | -14.84 Mn |
| Jun 30, 2022 | -14.84 Mn |
| Mar 31, 2022 | -6.80 Mn |
| Mar 31, 2022 | -6.80 Mn |
| Dec 31, 2021 | -17.83 Mn |
| Dec 31, 2021 | -17.83 Mn |
| Sep 30, 2021 | -9.16 Mn |
| Sep 30, 2021 | -9.16 Mn |
| Jun 30, 2021 | -11.17 Mn |
| Jun 30, 2021 | -11.17 Mn |
| Mar 31, 2021 | -14.15 Mn |
| Mar 31, 2021 | -14.15 Mn |
| Dec 31, 2020 | -14.52 Mn |
| Dec 31, 2020 | -14.52 Mn |
| Sep 30, 2020 | -8.58 Mn |
| Sep 30, 2020 | -8.58 Mn |
| Jun 30, 2020 | -7.13 Mn |
| Jun 30, 2020 | -7.13 Mn |
| Mar 31, 2020 | -7.98 Mn |
| Mar 31, 2020 | -7.98 Mn |
| Dec 31, 2019 | -5.25 Mn |
| Dec 31, 2019 | -5.25 Mn |